Clinical-stage TechBio company Recursion released positive Phase 1b/2 data. The ongoing TUPELO trial evaluates REC-4881. This drug is an investigational allosteric MEK1/2 inhibitor. Therefore, these results significantly advance FAP treatment. REC-4881 showed rapid and durable polyp burden reductions. Familial Adenomatous Polyposis (FAP) patients received the drug.
Specifically, researchers observed rapid clinical activity. Seventy-five percent of evaluable patients saw total polyp burden reductions. This happened after 12 weeks of treatment. Patients achieved a 43% median reduction in this period. Furthermore, the effect proved durable after stopping therapy. Eighty-two percent of patients maintained a reduction at Week 25. This was 12 weeks after completing the therapy. In fact, they observed a 53% median reduction from baseline. Natural history analysis shows that FAP is typically progressive.
Dr. Jessica Stout, TUPELO study Principal Investigator, praised the data. She noted the durable polyp burden reduction.
“The durable polyp burden reduction demonstrated by REC-4881 is highly encouraging for the FAP community. These Phase 2 results provide a meaningful basis for hope. They support a potential much-needed non-surgical option.”
Chris Gibson, Ph.D., Recursion’s CEO, validated their platform’s success. He noted the powerful role of the Recursion OS.
“These Phase 2 results mark a meaningful validation of the Recursion OS. This is a powerful example of how our platform can uncover therapeutic opportunities.”
The safety profile appears generally consistent with other MEK1/2 inhibitors. Recursion plans to approach the FDA in the first half of 2026. Ultimately, the company seeks to define a potential registration pathway. They also plan to expand eligibility to include younger patients. This news offers significant hope for future FAP treatment protocols. The data confirmed the utility of the AI-driven discovery platform in finding new solutions.
Explore Health-Tech News for the latest advancements in Healthcare Technology & insightful updates from industry experts!
News Source: GlobeNewswire.com
